AT

ATUM CO., LTD.

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.

355690 | KO

Overview

Corporate Details

ISIN(s):
KR7355690009
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로31길 38-9 에이스테크노타워1차 6층 603-2호, 구로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ATUM is a biotechnology company that provides integrated solutions and tools for the life sciences industry. Specializing in advanced bioengineering, the company offers services designed to accelerate timelines from discovery and preclinical research to manufacturing and Investigational New Drug (IND) applications. Its core offerings include gene design and synthesis, vector and sequence optimization, protein engineering, and the development of high-producing cell lines. Founded as DNA2.0 in 2003, ATUM operates on a collaborative model, partnering with researchers to advance their projects in molecular biology and protein engineering.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-29 00:00
Capital/Financing Update
타인에대한채무보증결정
Korean 10.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.8 MB
2025-05-07 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.1 KB
2025-05-02 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.4 KB
2025-04-29 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 65.7 KB
2025-04-29 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 57.6 KB
2025-04-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 70.0 KB
2025-04-29 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제4회차 CB)
Korean 6.0 KB
2025-04-02 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 14.9 KB
2025-04-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-03-31 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 49.2 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.9 KB
2025-03-28 00:00
Regulatory News Service
본점소재지변경
Korean 5.0 KB
2025-03-21 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 49.3 KB

Automate Your Workflow. Get a real-time feed of all ATUM CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ATUM CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ATUM CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH

Talk to a Data Expert

Have a question? We'll get back to you promptly.